IPSC (Century Therapeutics) Ending Cash Position: $53.8 Mil (As of Mar. 2026)


IPSC Century Therapeutics Inc IPSC
46 GF Score
Price $2.26
GF Value $38.99
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Century Therapeutics Ending Cash Position?

Century Therapeutics IPSC -2.60% 46 Ending Cash Position is $53.8 Mil as of Mar. 2026. GuruFocus rates IPSC with a GF Score™ of 46/100 and a GF Value™ of $38.99 (Possible Value Trap). The stock has 3 warning signs investors should review.

Century Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was $53.8 Mil.

Century Therapeutics's quarterly Ending Cash Position increased from Sep. 2025 ($58.7 Mil) to Dec. 2025 ($65.0 Mil) but then declined from Dec. 2025 ($65.0 Mil) to Mar. 2026 ($53.8 Mil).

Century Therapeutics's annual Ending Cash Position increased from Dec. 2023 ($49.3 Mil) to Dec. 2024 ($61.2 Mil) and increased from Dec. 2024 ($61.2 Mil) to Dec. 2025 ($65.0 Mil).

Century Therapeutics Ending Cash Position Related Terms

Century Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Century Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Century Therapeutics Ending Cash Position Chart

Century Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 58.16 86.24 49.30 61.21 65.01

Century Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.64 59.59 58.67 65.01 53.76
IPSC
46GF Score
Century Therapeutics Inc IPSC
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Century Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Century Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=61.213+3.798
=65.0

Century Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=65.011+-11.254
=53.8

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $53.8 Mil mean?
Century Therapeutics (IPSC) has a Ending Cash Position of $53.8 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Century Therapeutics and its competitors.
Is Century Therapeutics' Ending Cash Position too high?
Century Therapeutics' current Ending Cash Position is $53.8 Mil. Overall, Century Therapeutics has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Century Therapeutics' Ending Cash Position compare to PBYI and BNTC?
Century Therapeutics' Ending Cash Position of $53.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Century Therapeutics and its competitors. Century Therapeutics's current Ending Cash Position is $53.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Century Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Century Therapeutics (IPSC) is currently considered Possible Value Trap. The stock's GF Value™ is $38.99, compared to a current price of $2.26 — trading 94.2% below its estimated fair value. The current Ending Cash Position is $53.8 Mil. Century Therapeutics' overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Century Therapeutics (IPSC), the current Ending Cash Position is $53.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Century Therapeutics (IPSC) Overvalued in 2026?

Based on GuruFocus' analysis, Century Therapeutics stock appears to be undervalued. The current stock price of $2.26 is trading 94.2% below its estimated GF Value™ of $38.99. GuruFocus considers Century Therapeutics to be Possible Value Trap.

Key valuation signals for IPSC:

  • Ending Cash Position: $53.8 Mil
  • GF Value™: $38.99 vs. price of $2.26 (94.2% below fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the IPSC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Century Therapeutics Business Description

Address 25 N 38th Street, 11th Floor, Philadelphia, PA, USA, 19104
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
46GF Score

Get the complete analysis for IPSC

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.26
Price
$38.99
GF Value